These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31675459)

  • 1. Design and Analysis of the 4-Anilinoquin(az)oline Kinase Inhibition Profiles of GAK/SLK/STK10 Using Quantitative Structure-Activity Relationships.
    Asquith CRM; Laitinen T; Bennett JM; Wells CI; Elkins JM; Zuercher WJ; Tizzard GJ; Poso A
    ChemMedChem; 2020 Jan; 15(1):26-49. PubMed ID: 31675459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Water Network in Cyclin G-Associated Kinase (GAK) with 4-Anilino-quin(az)oline Inhibitors.
    Asquith CRM; Tizzard GJ; Bennett JM; Wells CI; Elkins JM; Willson TM; Poso A; Laitinen T
    ChemMedChem; 2020 Jul; 15(13):1200-1215. PubMed ID: 32358915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Optimization of 4-Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase.
    Asquith CRM; Laitinen T; Bennett JM; Godoi PH; East MP; Tizzard GJ; Graves LM; Johnson GL; Dornsife RE; Wells CI; Elkins JM; Willson TM; Zuercher WJ
    ChemMedChem; 2018 Jan; 13(1):48-66. PubMed ID: 29072804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a Potent Dual SLK/STK10 Inhibitor Based on a Maleimide Scaffold.
    Serafim RAM; Sorrell FJ; Berger BT; Collins RJ; Vasconcelos SNS; Massirer KB; Knapp S; Bennett J; Fedorov O; Patel H; Zuercher WJ; Elkins JM
    J Med Chem; 2021 Sep; 64(18):13259-13278. PubMed ID: 34463505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
    Asquith CRM; Naegeli KM; East MP; Laitinen T; Havener TM; Wells CI; Johnson GL; Drewry DH; Zuercher WJ; Morris DC
    J Med Chem; 2019 May; 62(9):4772-4778. PubMed ID: 30973735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacophore and 3D-QSAR characterization of 6-arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitors.
    Pan Y; Wang Y; Bryant SH
    J Chem Inf Model; 2013 Apr; 53(4):938-47. PubMed ID: 23496085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
    Assefa H; Kamath S; Buolamwini JK
    J Comput Aided Mol Des; 2003 Aug; 17(8):475-93. PubMed ID: 14703120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward the comprehensive systematic enumeration and synthesis of novel kinase inhibitors based on a 4-anilinoquinazoline binding mode.
    Kettle JG; Ward RA
    J Chem Inf Model; 2010 Apr; 50(4):525-33. PubMed ID: 20141221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase.
    Shewchuk L; Hassell A; Wisely B; Rocque W; Holmes W; Veal J; Kuyper LF
    J Med Chem; 2000 Jan; 43(1):133-8. PubMed ID: 10633045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of novel molecular probes of the Rio1 atypical protein kinase.
    Mielecki M; Krawiec K; Kiburu I; Grzelak K; Zagórski W; Kierdaszuk B; Kowa K; Fokt I; Szymanski S; Swierk P; Szeja W; Priebe W; Lesyng B; LaRonde-LeBlanc N
    Biochim Biophys Acta; 2013 Jul; 1834(7):1292-301. PubMed ID: 23523885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo design of protein kinase inhibitors by in silico identification of hinge region-binding fragments.
    Urich R; Wishart G; Kiczun M; Richters A; Tidten-Luksch N; Rauh D; Sherborne B; Wyatt PG; Brenk R
    ACS Chem Biol; 2013 May; 8(5):1044-52. PubMed ID: 23534475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D-QSAR and molecular docking studies of 4-anilinoquinazoline derivatives: a rational approach to anticancer drug design.
    Nandi S; Bagchi MC
    Mol Divers; 2010 Feb; 14(1):27-38. PubMed ID: 19330460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformation constraint of anilides enabling the discovery of tricyclic lactams as potent MK2 non-ATP competitive inhibitors.
    Xiao D; Palani A; Huang X; Sofolarides M; Zhou W; Chen X; Aslanian R; Guo Z; Fossetta J; Tian F; Trivedi P; Spacciapoli P; Whitehurst CE; Lundell D
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3262-6. PubMed ID: 23602398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design.
    Han W; Ding Y; Xu Y; Pfister K; Zhu S; Warne B; Doyle M; Aikawa M; Amiri P; Appleton B; Stuart DD; Fanidi A; Shafer CM
    J Med Chem; 2016 Apr; 59(7):3034-45. PubMed ID: 27002243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent antiviral activity of novel multi-substituted 4-anilinoquin(az)olines.
    Saul S; Pu SY; Zuercher WJ; Einav S; Asquith CRM
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127284. PubMed ID: 32631507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors.
    Lü S; Zheng W; Ji L; Luo Q; Hao X; Li X; Wang F
    Eur J Med Chem; 2013 Mar; 61():84-94. PubMed ID: 22867529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships.
    Asquith CRM; East MP; Laitinen T; Alamillo-Ferrer C; Hartikainen E; Wells CI; Axtman AD; Drewry DH; Tizzard GJ; Poso A; Willson TM; Johnson GL
    Eur J Med Chem; 2024 May; 271():116357. PubMed ID: 38636130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of 4-Anilinoquin(az)oline as a Cell-Active Protein Kinase Novel 3 (PKN3) Inhibitor Chemotype.
    Asquith CRM; Temme L; East MP; Laitinen T; Pickett J; Kwarcinski FE; Sinha P; Wells CI; Johnson GL; Zutshi R; Drewry DH
    ChemMedChem; 2022 Jun; 17(12):e202200161. PubMed ID: 35403825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma.
    Zhang M; Jiang L; Tao J; Pan Z; He M; Su D; He G; Jiang Q
    Bioorg Med Chem; 2019 Jun; 27(11):2268-2279. PubMed ID: 31014565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors.
    Waiker DK; Karthikeyan C; Poongavanam V; Kongsted J; Lozach O; Meijer L; Trivedi P
    Bioorg Med Chem; 2014 Mar; 22(6):1909-15. PubMed ID: 24530227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.